Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial

JAMA

Volumn 281, Issue 3, 1999, Pages 235-242

  Davidson, Michael H ^a   Hauptman, Jonathan ⁱ   DiGirolamo, Mario ^b   Foreyt, John P ^c   Halsted, Charles H ^d   Heber, David ^e   Heimburger, Douglas C ^f   Lucas, Charles P ^g   Robbins, David C ^h   Chung, Jain ⁱ   Heymsfield, Steven B ^j,k  

^a RADIANT RESEARCH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g WILLIAM BEAUMONT HOSPITAL   (United States)

^h Medlantic Research Institute   (United States)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^k NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; WEIGHT REDUCTION;

EID: 0033585499     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.3.235     Document Type: Article

References (30)

1. Flegal K, Carroll M, Kuczmarski R, Johnson C. Overweight and obesity in the United States. Int J Obes Relat Metab Disord. 1998;22:38-47.
2. Thomas PR, ed. Weighing the Options Criteria for Evaluating Weight-management Programs. Washington, DC: National Academy Press; 1995.
3. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-1915.
4. Eckel RH. Obesity and heart disease. Circulation. 1997;96:3248-3250.
5. Meigs J, Nathan D, Wilson P, Cupples L, Singer D. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. Ann Intern Med. 1998;128:524-533.
6. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;19:655-660.
7. Bray GA. Health hazards of obesity. Endocrinol Metab Clin North Am. 1996;25:907-919.
8. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995;19:221-226.
9. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
10. Williamson D. Intentional weight loss. Int J Obes Relat Metab Disord. 1997;21(suppl 1):S14-S19.
11. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
12. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA. 1996;276:637-639.
13. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill Book Co; 1971.
14. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-173.
15. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621-628.
16. Bray G. Evaluation of drugs for treating obesity. Obes Res. 1995;3(suppl 4):425S-434S.
17. Lean M Sibutramine. Int J Obes Relat Metab Disord. 1997;21(suppl 1):S30-S36.
18. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study, V (weeks 190 to 210). Clin Pharmacol Ther. 1992;51:615-618.
19. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51:642-646.
20. Wing R, Venditti E, Jakicic J, et al. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21:350-360.
21. Wing R, Blair E, Bononi P, et al. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care. 1994;17:30-36.
22. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(suppl 3):S12-S23.
23. Grundy S. Atherogenic dyslipidemia and the metabolic syndrome. In: Gotto AJ, ed. Drugs Affecting Lipid Metabolism. Norwell, Mass: Kluwer Academic Publishers; 1996:237-247.
24. Despres J, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
25. Landsberg L. Hyperinsulinemia. Hypertension. 1992;(suppl)19:161-166.
26. Volkmar FR, Stunkard AJ, Woolston J, Bailey RA. High attrition rates in commercial weight reduction patterns programs. Arch Intern Med. 1981;141:426-428.
27. Food and Drug Administration, Centerfor Drug Evaluation and Research. NDA 20-766, Xenical (Orlistat). Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting 69; March 1998; Gaithersburg, Md.
28. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995;35:1103-1108.
29. Ailison DB, Cappelleri JC, Carpenter KM. Design and analysis of obesity treatment and prevention trials. In: Dalton S, ed. Overweight and Weight Management. Gaithersburg, Md: Aspen Publishers Inc; 1997:557-597.
30. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with dropouts. Biometrics. 1996;52: 1324-1333.